Table 2.
Variable | Samples (n) | Blastocystis-positive (n)a | Blastocystis-positive (%) | 95% CI (%) | P value | Subtypes detectedb (n) |
---|---|---|---|---|---|---|
Bioregion | < 0.001 | |||||
BR1 | 21 | 8 | 38.1 | 18.1–61.6 | ST5 (8) | |
BR2 | 39 | 9 | 23.1 | 11.1–39.3 | ST5 (7), ST5/ST15 (1) | |
BR3 | 150 | 13 | 8.7 | 4.7–14.4 | ST5 (2) | |
BR4 | 8 | 0 | 0.0 | – | – | |
BR5 | 142 | 6 | 4.2 | 1.6–9.0 | ST5 (4) | |
Type of sampling site | < 0.001 | |||||
Hunting state | 197 | 22 | 11.2 | 7.1–16.4 | ST5 (9), ST5/ST15 (1) | |
Game reserve | 21 | 8 | 38.1 | 18.1–61.6 | ST5 (8) | |
Natural protected area | 97 | 4 | 4.1 | 1.1–10.2 | ST5 (4) | |
Urban/suburban | 45 | 2 | 4.4 | 0.5–15.2 | Not available | |
Sampling yearc | < 0.001 | |||||
2014 | 26 | 9 | 34.6 | 17.2–55.7 | ST5 (7), ST5/ST15 (1) | |
2018 | 148 | 6 | 4.1 | 1.5–8.6 | ST5 (4) | |
2019 | 52 | 6 | 11.5 | 4.3–23.4 | ST5 (2) | |
2020 | 70 | 5 | 7.1 | 2.4–15.9 | Not available | |
2021 | 60 | 9 | 15.0 | 7.1–26.6 | ST5 (7) |
95% confidence intervals (95% CI) are included. The values in bold represent statistical significance and subtypes previously reported in humans (regardeless of their true zoonotic potential).
aSamples were considered positive when Blastocystis was identified after Sanger and next-generation sequencing.
bSubtype information is only included for the 22 samples in which next-generation amplicon sequencing was conducted.
cFour samples from unknown sampling years, with one of the samples positive for Blastocystis ST5.